drugset / Trial / NCT02338635

Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis

NCT02338635

Phase 4 Unknown 55 enrolled Ewha Womans University
RandomizedParallel-groupTriple-blindTreatment

Summary

Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage during PD still remain unclear, generation of Endoplasmic reticulum (ER) stress may be responsible for progressive membrane dysfunction. Ursodeoxycholic acid (URSA) is a powerful inhibitor of ER stress to protect peritoneal fibrosis in peritoneal dialysis in the investigators in-vitro study. In this study the researchers investigated the hypothesis that URSA protect peritoneal membrane damage.

Timeline

Start
2015-07
Primary completion
2017-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule 100 mg